Vizsgálati helyszín
National Cancer Centre
Singapore, 168583, SzingapúrMég nincs intézményhez kötve
- 15futó vizsgálat
- 12lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis17 vizsgálat
- 2. fázis4 vizsgálat
- 1/2. fázis2 vizsgálat
- 2/3. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- Állapot
- Lezárult12 vizsgálat
- Fut, nem toboroz11 vizsgálat
- Toboroz4 vizsgálat
- Fő szponzor
- Hoffmann-La Roche20 vizsgálat
- Blueprint Medicines Corporation1 vizsgálat
- EMD Serono Research & Development Institute, Inc.1 vizsgálat
- HUYABIO International, LLC.1 vizsgálat
- Jazz Pharmaceuticals1 vizsgálat
- és még 3
Futó vizsgálatok
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775· 2. fázis· TORL Biotherapeutics, LLC· Forrás
Contact: Principal Investigator
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Breast Cancer Exercise Intervention Study
NCT05957068· National Cancer Centre, Singapore· Forrás
Contact: Dr Elaine LIM, MD, PhD
Toboroz
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562· 3. fázis· Jazz Pharmaceuticals· Forrás
Contact: Chee Kian Tham, MD
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· 3. fázis· HUYABIO International, LLC.· Forrás
Fut, nem toboroz
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499· 2/3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500· 1/2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552· 2/3. fázis· Hoffmann-La Roche· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek